AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently Amended) A stable ~~protein~~immunoglubulin preparation, wherein the preparation comprises ~~one or more stabilisers selected from the group consisting of non-polar and basic amino acids~~proline and wherein the preparation has a pH of 4.2 to 5.4, and wherein the preparation does not comprise nicotinamide.

2-3. (Cancelled)

4. (Currently Amended) The preparation of claim ~~3~~1, wherein proline is L-proline.

5. (Previously presented) The preparation of claim 1, wherein said preparation has a pH of 4.5 to 5.2.

6. (Previously presented) The preparation of claim 5, wherein said preparation has a pH of 4.6 to 5.0.

7. (Currently amended) The preparation of claim 1, wherein ~~said preparation comprises the one or more stabilisers at a~~the final concentration of proline is at least 0.2 M.

8. (Currently amended) ~~The preparation of claim 7,~~ A stable immunoglobulin preparation, wherein said preparation comprises ~~the one or more stabilisers at a~~proline and has a pH of 4.2 to 5.4, and wherein the final concentration of proline is between 0.2 to 0.4 M.

9. (Currently amended) The preparation of claim 1 or 8, wherein ~~said preparation comprises the one or more stabilisers at a~~the final concentration of proline is 0.25 M.

10. (Currently amended) The preparation of claim 1 or 8, wherein the ~~protein~~immunoglobulin concentration of said preparation is from 5 to 25% w/v.

11. (Currently amended) The preparation of claim 10, wherein the ~~protein~~immunoglobulin concentration of said preparation is from 15 to 20% w/v for subcutaneous administration.

12. (Currently amended) The preparation of claim 10, wherein the ~~protein~~immunoglobulin concentration of said preparation is from 6 to 15% w/v, for intravenous administration.

13. (Currently amended) The preparation of claim 12, wherein the ~~protein~~immunoglobulin concentration of said preparation is from 8 to 12% w/v.

14. (Cancelled)

15. (Currently amended) The preparation of claim ~~14~~1 or 8, wherein said preparation is an IgG, IgA or IgM preparation.

16. (Currently amended) A pharmaceutical composition comprising the ~~protein~~immunoglobulin preparation of claim ~~14~~1 or 8 and pharmaceutically acceptable additives.

17. (Cancelled)

18. (Withdrawn, currently amended) A method of stabilising ~~protein~~immunoglobulin preparations, comprising providing an aqueous ~~protein~~immunoglobulin solution and adding ~~one or more stabilisers selected from the group consisting of basic and non-polar amino acids~~proline, wherein the pH of the solution is adjusted to a pH of about 4.2 to 5.4, and wherein the preparation does not comprise nicotinamide.

19. (Cancelled)

20. (Withdrawn) The method of claim 18, wherein the pH is adjusted to 4.8.

21. (Withdrawn) The method of claim 18, wherein the final concentration of the ~~one or more stabilisers~~proline is adjusted to between 0.2 to 0.4 M.

22. (Cancelled)

23. (Currently amended) A pharmaceutical composition comprising the ~~protein~~immunoglobulin preparation of claim 1 and pharmaceutically acceptable additives.

24. (New) A method of decreasing aggregate formation and/or of decreasing colouring of immunoglobulin preparations, comprising providing an aqueous immunoglobulin solution and adding one or more stabilisers chosen from non-polar amino acids, wherein the pH of the solution is adjusted to a pH of about 4.2 to 5.4.

25. (New) The method of claim 25, wherein the pH is adjusted to 4.8.

26. (New) The method of claim 25, wherein the non-polar amino acid is proline.

27. (New) The method of claim 26, wherein the proline concentration is adjusted to between 0.2 to 0.4 M.

28. (New) The preparation of claim 1 or 8, wherein the final concentration of proline is between 0.2 to 0.3 M.